BUY – Cochlear Limited (ASX:COH)
Cochlear Limited (COH) is the global leader in premium implanted hearing aid technology, selling devices around the world that are widely considered the best and most reliable due to their unique proprietary technology.
COH’s recent US FDA approvals for devices that can be monitored and maintained over cloud-based software shows it’s at the forefront of technology in its sector.
Unfortunately, the COVID-19 pandemic has led to restrictions (delays) on elective surgeries, impacting short term cash-flows/profits. Prudently, the company raised fresh equity to bolster an already conservative balance sheet to fund help fund future growth.
While the implanting of hearing aids has been considered elective in many countries – and consequently patients have been unable to undergo operations as hospitals have been prioritising COVID-19 activities – and patients have avoided non-emergency hospitalisation, the reality is that the majority of these hearing-impaired patients will still require an implant.
More so than many discretionary industries, demand (sales) in critical healthcare has merely been delayed, not lost, and recent anecdotal reports suggest that a very large backlog of implant demand has built up and medical professionals in the industry are beginning to plan a mass-scale return to operations, with surgery numbers as much as double the ‘normal’ level once fully open.
Since delivering better than expected half-year results in mid-August, showing excellent cost controls and a moderate recovery in demand, COH shares have retreated some 14% amidst a minor market pullback in recent weeks. We see this as an excellent opportunity to add to your portfolio, in what is a world-leading hearing aid (Cochlear implants) developer, at very attractive prices ahead of a strong recovery expected in late 2020 and 2021.
This document has been prepared for the general information of investors and not having regard to any particular person’s financial situation, objectives or needs. Accordingly, in so far as any information may constitute advice (whether express or implied), it is general advice and no recipient should rely upon it without having obtained specific advice from their advisor at Baker Young Limited. Baker Young Limited makes no representation, gives no warranty and does not accept any responsibility for the accuracy or completeness of any recommendation, information or advice contained herein. To the extent permitted by law, Baker Young Limited will not be liable to the recipient or any other persons in contract, in tort or otherwise for any loss or damage (including indirect or consequential loss) as a result of the recipient, or any other person acting or refraining from acting in reliance on any recommendation, information or advice herein. Baker Young Limited or persons associated with it, may have an interest in the securities or financial products mentioned in this document and may earn brokerage and other fees as a result of transactions in any such securities. Australian Financial Services Number 246735.